Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
The deal is a late entrant into 2020's top five mergers and acquisitions.
Digital therapeutics are going from strength to strength during the pandemic.
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Astrazeneca and Amgen hope the “totality of the data” will win out for their asthma project.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.